Compare
USANA Health Sciences Inc vs Tilray Brands, Inc. vs Curaleaf Holdings, Inc. vs Cronos Group Inc.
| Latest fiscal year | USANA Health Sciences Inc USNA | Tilray Brands, Inc. TLRY | Curaleaf Holdings, Inc. CURLF | Cronos Group Inc. CRON |
|---|---|---|---|---|
| Year ended | 2026-01-03 | 2026-05-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $925.26M | $915.45M | $1.27B | $146.59M |
| Revenue growth (YoY) | +8.3% | +11.5% | -5.0% | +24.6% |
| Gross margin | 78.3% | 28.4% | 49.8% | 42.8% |
| Operating margin | 4.0% | -6.9% | 2.0% | -11.9% |
| Net margin | 1.2% | -13.3% | -18.2% | -6.4% |
| Net income | $10.76M | -$121.40M | -$231.07M | -$9.45M |
| EPS (Diluted) | $0.58 | -$1.09 | -$0.35 | -$0.02 |
| Operating cash flow | $22.35M | -$69.14M | $137.71M | $25.87M |
| Free cash flow | $8.53M | n/a | $74.27M | $149.0K |
| Cash & equivalents | $158.38M | $225.98M | n/a | $791.79M |
| Total assets | $742.91M | $2.33B | $2.85B | $1.20B |
| Total liabilities | $156.64M | $733.14M | $2.01B | $54.18M |
| Shareholders' equity | $533.10M | $1.61B | $756.35M | $1.14B |
| Return on year-end equity | 2.0% | -7.5% | -30.6% | -0.8% |
| Shares outstanding | 18.28M | 131.68M | n/a | 381.59M |
Revenue, most recent five fiscal years
| Fiscal year | USANA Health Sciences Inc | Tilray Brands, Inc. | Curaleaf Holdings, Inc. | Cronos Group Inc. |
|---|---|---|---|---|
| Latest | $925.26M Ended 2026-01-03 | $915.45M Ended 2026-05-31 | $1.27B Ended 2025-12-31 | $146.59M Ended 2025-12-31 |
| 1 year earlier | $854.50M Ended 2024-12-28 | $821.31M Ended 2025-05-31 | $1.33B Ended 2024-12-31 | $117.61M Ended 2024-12-31 |
| 2 years earlier | $921.01M Ended 2023-12-30 | $788.94M Ended 2024-05-31 | $1.35B Ended 2023-12-31 | $87.24M Ended 2023-12-31 |
| 3 years earlier | $998.60M Ended 2022-12-31 | $627.12M Ended 2023-05-31 | $1.28B Ended 2022-12-31 | $86.75M Ended 2022-12-31 |
| 4 years earlier | $1.19B Ended 2022-01-01 | $628.37M Ended 2022-05-31 | $1.20B Ended 2021-12-31 | $64.56M Ended 2021-12-31 |